<scp>AT</scp>‐1001: a high‐affinity α3β4 <scp>nAChR</scp> ligand with novel nicotine‐suppressive pharmacology

Abstract

These findings describe a more complex AT-1001 in vitro profile than previously appreciated and provide further support for the potential of AT-1001 and congeners as clinically useful compounds for smoking cessation, with a mechanism of action distinct from currently available medications.